In this article, I will feature one healthcare company that has seen intensive insider buying during the last 30 days. Intensive insider buying can be defined by the following three criteria:
- The stock is purchased by three or more insiders within one month.
- The stock is sold by no insiders in the month of intensive purchasing.
- At least two purchasers increase their holdings by more than 10%.
Navidea Biopharmaceuticals (NYSEMKT:NAVB), a biopharmaceutical company, engages in the development and commercialization of precision diagnostics and radiopharmaceutical agents.
Insider buying during the last 30 days
Here is a table of Navidea's insider-trading activity during the last 30 days by insider.
|Name||Title||Trade Date||Shares Purchased||Current Ownership||Increase In Shares|
|Brendan Ford||Director||Nov 8||20,000||139,250 shares||+16.8%|
|Frederick Cope||SVP||Nov 8||3,500||99,451 shares||+3.6%|
|Gordon Troup||Director||Nov 8||20,000||146,250 shares||+15.8%|
|Mark Pykett||CEO||Nov 8||10,900||406,625 shares||+2.8%|
|Brent Larson||CFO||Nov 8||5,000||380,521 shares||+1.3%|
There have been 59,400 shares purchased by insiders during the last 30 days.
Insider buying by calendar month
Here is a table of Navidea's insider-trading activity by calendar month.
|Month||Insider buying / shares||Insider selling / shares|
There have been 95,750 shares purchased and there have been zero shares sold by insiders this year. The month of November has seen the most insider buying.
Navidea reported the third-quarter financial results on November 6 with the following highlights:
|Net loss||$11.3 million|
During the fourth quarter of 2013, Navidea expects additional value enhancing events, including submission of the Lymphoseek sNDA, EMA feedback on its Marketing Authorization Application in Europe, initiation of the NAV5001 Phase 3 trial in Parkinson's disease and additional disclosures regarding the advance of the company's Manocept platform.
Here is a table of these competitors' insider-trading activities this year.
|Company||Insider buying / shares||Insider selling / shares|
Only Navidea has seen intensive insider buying during the last 30 days.
There have been five different insiders buying Navidea and there have not been any insiders selling Navidea during the last 30 days. Two of these five insiders increased their holdings by more than 10%. Navidea has an insider ownership of 3.72%.
There are five analyst buy ratings, one neutral rating, and one sell rating with an average price target of $5.25. I believe the next major catalyst for the stock will be the possible positive CHMP opinion for Lymphoseek later this year. I have a long position in the stock currently.
Disclosure: I am long NAVB. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.